Literature DB >> 27521875

Alternatives to Hysterectomy: Management of Uterine Fibroids.

Shannon K Laughlin-Tommaso1.   

Abstract

Uterine fibroids are a common condition that can be debilitating and are the leading benign cause of hysterectomy. Women often live with the symptoms rather than choose hysterectomy, but survey studies have shown that work, social life, and physical activities are hindered by fibroid symptoms. Offering alternative therapies tailored to a woman's symptoms will allow her to choose a treatment that fits her needs and to preserve her uterus and fertility. The minimally invasive treatment options have a faster recovery and lower surgical risk than hysterectomy, but may require reintervention. One pharmacologic treatment offers short-term, intermittent therapy with lasting effects.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Fibroids; Focused ultrasound ablation; Myomectomy; Ulipristal acetate; Uterine artery embolization

Mesh:

Substances:

Year:  2016        PMID: 27521875     DOI: 10.1016/j.ogc.2016.04.001

Source DB:  PubMed          Journal:  Obstet Gynecol Clin North Am        ISSN: 0889-8545            Impact factor:   2.844


  3 in total

Review 1.  Updated approaches for management of uterine fibroids.

Authors:  Aymara Mas; Marta Tarazona; Joana Dasí Carrasco; Gloria Estaca; Ignacio Cristóbal; Javier Monleón
Journal:  Int J Womens Health       Date:  2017-09-05

2.  Health-Related Quality of Life With Ulipristal Acetate for Treatment of Uterine Leiomyomas: A Randomized Controlled Trial.

Authors:  Andrea S Lukes; David Soper; Amanda Harrington; Vilma Sniukiene; Yifan Mo; Patrick Gillard; Lee Shulman
Journal:  Obstet Gynecol       Date:  2019-05       Impact factor: 7.661

3.  Laparotomic myomectomy for a huge cervical myoma in a young nulligravida woman: A case report and review of the literature.

Authors:  Hatem Abu Hashim; Moustafa Al Khiary; Mohamed El Rakhawy
Journal:  Int J Reprod Biomed       Date:  2020-02-27
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.